Check of APpropriaTeness of Antimicrobial therapy In Nursing homes (CAPTAIN):a point prevalence study in Belgium.


Journal

JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 17 04 2024
accepted: 13 06 2024
medline: 8 7 2024
pubmed: 8 7 2024
entrez: 8 7 2024
Statut: epublish

Résumé

The overall prevalence of antimicrobial therapy (AMT) in nursing homes is well described. However, less is known about the appropriateness of AMT in nursing home residents. Therefore, the Check of APpropriaTeness of antimicrobial therapy in nursing homes (CAPTAIN) study aimed to assess both prevalence and appropriateness of AMT in Belgian nursing homes. In a prospective, observational, point prevalence study, researchers documented prevalence and identified potentially inappropriate prescriptions (PIPs) by evaluating accordance of AMT with national guidelines. The severity of inappropriateness was assessed by a modified Delphi expert panel. Eleven nursing homes, including 1178 residents, participated in this study. On the survey day, 8.0% of residents took systemic AMT, primarily for urinary tract infections (54.2%), respiratory tract infections (36.5%), and skin and skin-structure infections (6.3%). About half of these prescriptions were used in prophylaxis (52.1%). Registration of indication and stop date was missing in 58.3% and 56.3% of AMTs, respectively. In 89.6% of the systemic AMTs, at least one discordance with national guidelines was identified, resulting in a total of 171 PIPs, with 49 unique PIPs. Of all unique PIPs, 26.5% were assessed with a high severity score (≥4). According to the expert panel, most inappropriate practice was starting AMT for cough without other symptoms. Inappropriate timing of time-dependent AMTs was common, but assessed as 'moderately severe'. One-third of systemic AMT exceeded the recommended duration. AMT in nursing homes is often not prescribed according to national guidelines, highlighting the need for future interventions to promote the rational use of AMT in this setting.

Identifiants

pubmed: 38974942
doi: 10.1093/jacamr/dlae101
pii: dlae101
pmc: PMC11227214
doi:

Types de publication

Journal Article

Langues

eng

Pagination

dlae101

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Auteurs

Indira Coenen (I)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.

Lotte Vander Elst (L)

University Hospitals Leuven, Pharmacy Department, Leuven, Belgium.

Isabel Spriet (I)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
University Hospitals Leuven, Pharmacy Department, Leuven, Belgium.

Matthias Gijsen (M)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
University Hospitals Leuven, Pharmacy Department, Leuven, Belgium.

Veerle Foulon (V)

KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.

Jan De Lepeleire (J)

KU Leuven, Department of Public Health and Primary Care, Leuven, Belgium.

Katrien Latour (K)

KU Leuven, Department of Public Health and Primary Care, Leuven, Belgium.
Sciensano, Department of Epidemiology and Public Health, Brussels, Belgium.

Veerle Cossey (V)

University Hospitals Leuven, Department of Infection Control and Epidemiology, Leuven, Belgium.

Annette Schuermans (A)

KU Leuven, Department of Public Health and Primary Care, Leuven, Belgium.
University Hospitals Leuven, Department of Infection Control and Epidemiology, Leuven, Belgium.

Nele Stroobants (N)

University Hospitals Leuven, Department of Infection Control and Epidemiology, Leuven, Belgium.

Charlotte Quintens (C)

University Hospitals Leuven, Pharmacy Department, Leuven, Belgium.

Classifications MeSH